HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Benznidazole

HCID 31593
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
22994-85-0
Standard SMILES
O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1
InChIKey
CULUWZNBISUWAS-UHFFFAOYSA-N
Molecular formula
C12H12N4O3
Average molar mass
260.25 g/mol
Monoisotopic mass
260.09094026

Overview

Benznidazole is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease. It has a role as an antiprotozoal drug. It is a member of imidazoles, a monocarboxylic acid amide and a C-nitro compound.

Names & identifiers

Preferred name
Benznidazole
IUPAC
N-benzyl-2-(2-nitroimidazol-1-yl)acetamide
English name
Benznidazole
Molecular formula
C12H12N4O3
Molecular weight
260.25

Names & synonyms

BENZNIDAZOLE22994-85-0BenznidazolRadanilBenzonidazoleRochaganbenzonidazolBenznidazolumN-benzyl-2-(2-nitroimidazol-1-yl)acetamideRo 07-10511H-Imidazole-1-acetamide, 2-nitro-N-(phenylmethyl)-N-Benzyl-2-nitroimidazole-1-acetamide
Show more names
ro71051Aids007909NSC 299972Aids-007909
2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamideN-Benzyl-2-nitroimidazol-1-yl-acetamideImidazole-1-acetamide, N-benzyl-2-nitro-DTXSID9046570YC42NRJ1ZDN-benzyl-2-nitro-1-imidazoleacetamideNSC-299972Ro-7-1051

Database identifiers

CAS
22994-85-0
PubChem CID
31593
DTXSID
DTXSID9046570
ChEMBL
CHEMBL110
ChEBI
CHEBI:133833
UNII
YC42NRJ1ZD
EC Number
624-902-4
Nikkaji
J2.765K

Properties

Computed structural propertiesFilling in

XLogP
0.9
Topological polar surface area
92.7 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
4
Rotatable bonds
4
Heavy atoms
19
Formal charge
0
Complexity
325

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LogP0.85
Solubility>39 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs · 4 items

Breast Feeding; Lactation; Milk, Human; Antiparasitic Agents; Antiprotozoal Agents; Nitroimidazoles; Trypanocidal Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

American trypanosomiasis

Melting Point190-192

Physicochemical properties

Melting point
189 · 189-192 °C (lit.)
Density
1.35 · 1.35±0.1 g/cm3(Predicted)
storage temp.
Sealed in dry,Room Temperature
solubility
50 mg/mL, · methanol: soluble50mg/mL, clear, colorless to yellow
pka

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H315 (97.6%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesSkin Irrit. 2 (97.6%)

Toxicology

Hepatotoxicity · 1 item

Benznidazole therapy is associated with an appreciable rate of serum enzyme elevations, found in at least 10% of patients. The abnormalities, however, are generally mild, transient and without accompanying symptoms or jaundice. In clinical trials there were no reported instances of clinically apparent liver injury with jaundice attributed to benznidazole. However, since its approval and more widescale use, there have been several case reports of drug rash with eosinophilia and systemic symptoms (DRESS syndrome) accompanied by serum enzyme elevations associated with benznidazole therapy, one of which was accompanied by jaundice. Furthermore, cases of immunoallergic hepatitis have been reported with other more commonly used nitroimidazoles such as metronidazole and ornidazole, some of which have been severe. Thus, benznidazole therapy has had limited clinical use, but it appears to have the potential to cause symptomatic, immunoallergic hepatitis with jaundice.

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Chemistry & industry

Pharmacology

ATC Code · 2 items

P - Antiparasitic products, insecticides and repellents

P01CA02

PharmacodynamicsBenznidazole is a trypanocidal agent which kills the causative organism in Chagas disease, *Trypanosoma cruzi*.
Mechanism of Action · 1 item

Benznidazole is thought to be reduced to various electrophilic metabolites by nitroreductases present in *Trypanosoma cruzi*. These metabolites likely bind to proteins, lipids, DNA, and RNA resulting in damage to these macromolecules. Benznidazole has been found to increase trypanosomal death through interferon-γ which is likely present in increased amounts due to inflammation caused by macromolecule damage. DNA in parasites affected by benznidazole has been found to undergo extensive unpacking with overexpression of DNA repair proteins supporting the idea of DNA damage contributing to the mechanism of the drug.

Biological Half-LifeThe half life of elimination is 13.27 h.
Metabolism/MetabolitesBenznidazole is metabolized by nitroreductases in *Trypanosoma cruzi* and by cytochrome P450 enzymes.
MeSH Pharmacological Classification · 3 items

Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.

Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes.

Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA.

Absorption, Distribution and Excretion

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
14 · 14+-.0.46(Predicted)
form
Solid
color
White to Off-White
Water Solubility
0.4 g/L · 0.4g/L(temperature not stated)
Merck
13 · 13,1085
BCS Class
3 · 3
InChI
1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)
InChIKey
CULUWZNBISUWAS-UHFFFAOYSA-N
SMILES
[O-][N+](=O)c1nccn1CC(=O)NCc2ccccc2
FDA UNII
42 NRJ1ZD · YC42NRJ1ZD
ATC code
1 CA02 · P01CA02
UNSPSC Code
12352100 · 12352100
NACRES
22 · NA.22
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
315 · H315-H319-H335
Precautionary statements
261 · P261-P264-P271-P280-P302+P352-P305+P351+P338
target organs
Respiratory system
PPE
95 · dust mask type N95 (US), Eyeshields, Gloves
Hazard Codes
Xi
Risk Statements
36 · 36/37/38
Safety Statements
26 · 26-36
WGK Germany
3 · 3
RTECS
3340000 · NI3340000
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
2 Skin · Eye Irrit. 2Skin Irrit. 2STOT SE 3

Benznidazole

Ambiguous-DILI-concern

2

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

PPE
dust mask type N95 (US), Eyeshields, Gloves
wgk
3
rtecs
NI3340000
risk_code
36/37/38
Signal word
Warning
Symbol(GHS)
GHS07
hazard_code
Xi
safety_code
26-36
Storage Class
11 - Combustible Solids
target organs
Respiratory system
Hazard statements
H315-H319-H335
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2STOT SE 3
Precautionary statements
P261-P264-P271-P280-P302+P352-P305+P351+P338
· 4 items

Benznidazole has a bioavailability of 91.7% and a Tmax of 2.93 h.

The metabolites of benznidazole appear to be primarily exreted in the urine.

The apparent volume of distribution is 39.19 L.

The apparent oral clearance is 2.04 L/h.

Applications · 5 items

DescriptionBenznidazole is the second of the drugs approved for treatment of Chagas' disease. Like nifurtimox, it is effective against the circulating form of Trypanosoma cruzi during the acute phase of the disease, but also like nifurtimox, it is ineffective during the chronic stage of the disease.

DescriptionBenznidazole is an orally bioavailable antiprotozoal agent. It is a 2-nitroimidazole prodrug that becomes active when the nitro group is reduced within the parasite. It inhibits the growth of the parasites T. cruzi, T. vaginalis, G. lamblia, and E. histolytica (IC50s = 8.1, 18.62, 22.58, and 4.27 μM, respectively). It also inhibits clonogenic growth of human C33A cervical and KNS42 glioblastoma cancer cells under hypoxic, but not normoxic, conditions when used at a concentration of 100 μM. Benznidazole (100 mg/kg per day) decreases T. cruzi blood parasitemia to below detectable levels in a mouse model of chronic stable Chagas disease. Formulations containing benznidazole have been used in the treatment of Chagas disease caused by T. cruzi.

UsesN-Benzyl-2-nitro-1H-imidazole-1-acetamide (Benznidazole) may be used as reference drug for the extraction of guaianolide from the aerial parts of Tanacetum parthenium and to evaluate its in vitro antiprotozoal activity.

UsesBenznidazole (BNZ) is traditionally used to treat Chagas disease caused by Trypanosoma cruzi. The drugs used for the treatment of this disease, Nifurtimox and Benznidazole, are toxic and present sever e side effects.

General DescriptionN-Benzyl-2-nitro-1H-imidazole-1-acetamide (Benznidazole) is a nitro-heterocyclic compound. It is widely employed drug for the treatment of Chagas disease. It exhibits three polymorphic forms..

Additional notes

DefinitionChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.